Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.54 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.54 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023951 | 0.80 | MGLL (0.40) | MGLLKDM1AUSP30BRD4CREBBP | |
| SCHEMBL31023764 | 0.79 | MGLL (0.38) | MGLLFAAH | |
| SCHEMBL31023913 | 0.79 | MGLL (0.46) | MGLLFAAH | |
| SCHEMBL21802546 | 0.78 | PLA2G7 (0.68) | MGLLPLA2G7ABHD6BRD4CREBBP | |
| SCHEMBL31023788 | 0.77 | CACNA2D1 (0.47) | MGLLFAAH | |
| SCHEMBL31023841 | 0.77 | FAAH (0.39) | MGLLFAAH | |
| SCHEMBL31023782 | 0.77 | MGLL (0.39) | MGLLFAAH | |
| SCHEMBL31023956 | 0.76 | MGLL (0.45) | MGLLFAAH | |
| SCHEMBL31023920 | 0.76 | MGLL (0.51) | MGLLPLA2G7ABHD6FAAHKDM1A | |
| SCHEMBL31023814 | 0.75 | OGA (0.40) | MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | MGLL 1/4885PLA2G7 72/4885ABHD6 18/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | MGLL 1/4885PLA2G7 72/4885ABHD6 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.